Compare MTEX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | BIVI |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 11.5M |
| IPO Year | 1998 | 2013 |
| Metric | MTEX | BIVI |
|---|---|---|
| Price | $5.50 | $1.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.5K | ★ 106.8K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $108,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.80 | $0.88 |
| 52 Week High | $12.45 | $9.09 |
| Indicator | MTEX | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 57.50 |
| Support Level | $4.47 | $1.17 |
| Resistance Level | $5.83 | $1.71 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 92.12 | 68.75 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.